UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
Program to Highlight UGN-102 and Company’s Innovative Early-stage Pipeline Programs
Company to Report Third Quarter 2021 Financial Results on
In addition to presentations from UroGen’s Chairman
Please register for the webinar on the Company's website at www.urogen.com under the Events & Presentations section of the Investor Relations site (https://investors.urogen.com/events-and-presentations).
Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.
Third Quarter 2021 Financial Results
Additionally, the Company announced that it will report third quarter 2021 financial results on
The webcast will be available on the Investors section of the Company’s website at http://investors.urogen.com. Following the live audio webcast, a replay will be available on the Company's website for 30 days.
Live (International): (615) 247-5916
Confirmation number: 1908609
UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in